Third time the charm for Alzheimer's drug?

Share this article:

Eli Lilly's experimental Alzheimer's treatment was ruled a failure in two earlier trials. But when investigators combined solanezumab's data from both tests, they discovered that cognitive declines were slowed by 34% among patients who started out with mild symptoms. Based on those results, solanezumab has been selected for a federally sponsored study for people who have not yet suffered significant memory loss. Brigham and Women's Hospital is helping coordinate the three-year investigation, which could cost up to $100 million."This is the first time investigators will test an amyloid-clearing drug in older individuals thought to be in the pre-symptomatic stage of Alzheimer's disease," the hospital announced. They are hoping the medication will reduce memory decline by 30%.

Share this article:

More in Products

Last day to enter McKnight's Tech Awards

Today is the final day to submit entries into the third annual McKnight's Excellence in Technology Awards.

AliMed offers three new fall management products

AliMed offers three new fall management products

AliMed is now offering the AliMed CordLess® Sensor Alarm and the AliMed Worry-Free Fall Alarm to help reduce the risk of accidental falls, and the HipShield® X-tra to help prevent ...

Diamond Wipes creates new wipes

Diamond Wipes creates new wipes

Diamond Wipes has announced an updated version of its Handyclean™ cleaning and sanitizing wipes.